Introduction: Leishmaniasis is a disease with high mortality rates and approximately 1.5
million new cases each year. Despite the new approaches and advances to fight the …

Leishmaniasis is a disease with high mortality rates and approximately 1.5 million new
cases each year. Despite the new approaches and advances to fight the disease, there are …

Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting
millions of people, mainly in tropical countries, due to poor social conditions and low …

In the pursuit of developing novel anti-leishmanial agents, we conducted an extensive
computational study to screen inhibitors from the FDA-approved ZINC database against …

Leishmaniasis is a parasitic disease with frequent annual incidence. An important issue in
chemotherapy is the emergence of resistance, toxicity and lack of cost-effectiveness within …

Background: Leishmaniasis is a neglected tropical disease associated with several clinical
manifestations, including cutaneous, mucocutaneous, and visceral forms. As currently …

Leishmaniasis is a complex disease; it is classified under neglected diseases and it causes
significant health problems in many developing countries. Even though some drugs are …

Leishmaniasis is one of the most important neglected tropical diseases (NTDs) that are
especially common among low-income populations in developing regions of Africa, Asia …

Background: Visceral leishmaniasis (VL) is a tropical neglected disease, which encounters
poorest of poor people living in Asia, Africa and Latin America; causing the mortality of more …

Arginase catalyzes the hydrolysis of l-arginine into l-ornithine and urea, acting as a key
enzyme in the biosynthesis of polyamines. Leishmania growth and survival is dependent on …